Also found in: Medical.
NK1Neurokinin Receptor 1
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK1 RA to significantly reduce CINV in both the acute phase (0 - 24 hours after chemotherapy) and the delayed phase (24 - 120 hours after chemotherapy).
In samples collected after 45 days of incubation, diabetic mice presented a reduced influx of TCD4+ cells (CD3+/CD4+; Figure 4(a)), TCD8+ cells (CD3+/CD8+; Figure 4(b)), B lymphocytes (CD19+; Figure 4(c)), NK cells (NK1.1+/CD3-; Figure 4(d)), and dendritic cells (CD11c+/CD80+; Figure 4(f)) when compared to control infected groups.
Maggi, "Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors," British Journal of Cancer, vol.
O maropitant e um anti-emetico de acao central que atua bloqueando os receptores da neurocinina-1 (NK1) no SNC.
Now working their way through the developmental pipeline are two promising novel classes of drugs designed to target the physiologic mechanisms underlying this common and challenging problem: neurokinin 1 (NK1) receptor antagonists and selective opioid receptor agonists, explained Dr.
Aprepitant belongs to a class of agents known as NK1 receptor antagonists, which are often used in combination with 5-HT3 receptor antagonists for the prevention of CINV.
Upon removal of red bodies and centrifugation, immune cells were incubated with fluorochrome-conjugated antibodies and characterized according to two different panels, a myeloid panel: CD45-BV510 (103138, BioLegend), 7AAD-PE-Cy5-YG (420404, BioLegend), CD11b-BV711 (101242, BioLegend), F4/80APC (17-4801-82, eBiosciences), MHC2-Alexa700 (107622, BioLegend), CD11c-PE-Cy7 (25-0114-81, eBiosciences), and Ly6G-FITC (551460, BD Pharmingen) and a lymphoid panel: CD45-BV510 (103138, BioLegend), 7AAD-PE-Cy5-YG (420404, BioLegend), CD3-PE-Cy7 (25-0031-82, eBiosciences), CD4-FITC (11-0041-85, eBiosciences), CD8-PerCpCy5.5 (126610, BioLegend), and NK1.1-BV711 (108745, BioLegend).
Wang, "Increased expression of SP and NK1 receptor in rat colon of chronic visceral hypersensitivity," Chinese Journal of Gastroenterology & Hepatology, vol.
Aprepitant is a neurokinin-1 (NK1) receptor antagonist and is the first of its class to be approved for use [3].